880180 | C16 PEG2000 Ceramide
N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]}
Please Confirm Your Location
Effective March 1, 2018, Merck KGaA, Darmstadt, Germany* is the exclusive Distributor of Avanti Research. Research Products for all countries except the United States. For product pricing and order placement, please click on the appropriate Location Box below.
For customers located outside the United States, you will be redirected to www.sigmaaldrich.com/avanti prior to completing your purchase. Thank you for your continued business and support of Avanti Research!
*The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada
C16 PEG2000 Ceramide
N-palmitoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]}
Representative Structure
The molecular weight and exact mass are averages based on the polydispersity of PEG.
C129H253NO51 (average MW due to polydispersity of PEG)
C 58.81%, H 9.68%, N 0.53%, O 30.97%
CAS Registry Number is a Registered Trademark of the American Chemical Society
Powered by BiozFattore L, Campani V, Ruggiero CF, Salvati V, Liguoro D, Scotti L, Botti G, Ascierto PA, Mancini R, De Rosa G, Ciliberto G. In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma. Int J Mol Sci. 2020 Mar 12;21(6):1930. doi: 10.3390/ijms21061930. PMID: 32178301; PMCID: PMC7139872.
PubMed ID: 32178301Thanki K, van Eetvelde D, Geyer A, Fraire J, Hendrix R, Van Eygen H, Putteman E, Sami H, de Souza Carvalho-Wodarz C, Franzyk H, Nielsen HM, Braeckmans K, Lehr CM, Ogris M, Foged C. Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration. J Control Release. 2019 Sep 28;310:82-93. doi: 10.1016/j.jconrel.2019.08.004. Epub 2019 Aug 6.
PubMed ID: 31398360Thanki K, Papai S, Lokras A, Rose F, Falkenberg E, Franzyk H, Foged C. Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery. Pharm Res. 2019 Jan 9;36(3):37. doi: 10.1007/s11095-018-2566-3.
PubMed ID: 30623253Maroof H, Islam F, Dong L, Ajjikuttira P, Gopalan V, McMillan NAJ, Lam AK. Liposomal Delivery of miR-34b-5p Induced Cancer Cell Death in Thyroid Carcinoma Cells. 2018 Dec 11;7(12). pii: E265. doi: 10.3390/cells7120265.
PubMed ID: 30544959- Certificate of Analysis (Lot No. 880180P-1G-A-025 and 6300PQA025)
- Certificate of Analysis (Lot No. 880180P-200MG-A-025 and 6300PNA025)
- Certificate of Analysis (Lot No. 880180P-25MG-A-025 and 6300PJA025)
- Certificate of Analysis (Lot No. 880180P-500MG-A-025 and 6300PPA025)
- Certificate of Analysis (Lot No. 880180P-1G-A-026 and 6300PQA026)
- Certificate of Analysis (Lot No. 880180P-200MG-A-026 and 6300PNA026)
- Certificate of Analysis (Lot No. 880180P-25MG-A-026 and 6300PJA026)
- Certificate of Analysis (Lot No. 880180P-200MG-B-026 and 6300PNB026)
- Certificate of Analysis (Lot No. 880180P-200MG-C-026 and 6300PNC026)
- Certificate of Analysis (Lot No. 880180P-25MG-B-025 and 6300PJB025)
- Certificate of Analysis (Lot No. 880180P-200MG-B-025 and 6300PNB025)
- Certificate of Analysis (Lot No. 880180P-200MG-D-026 and 6300PND026)
- Certificate of Analysis (Lot No. 880180P-200MG-E-026 and 6300PNE026)
- Certificate of Analysis (Lot No. 880180P-200MG-B-033 and 6300PNB033)
- Certificate of Analysis (Lot No. 880180P-25MG-B-033 and 6300PJB033)
- Certificate of Analysis (Lot No. 880180P-200MG-C-033 and 6300PNC033)
- Certificate of Analysis (Lot No. 880180P-25MG-C-033 and 6300PJC033)
- Certificate of Analysis (Lot No. 880180P-25MG-A-034 and 6300PJA034)
